Abiomed set to conquer the heart's last frontier
This article was originally published in Clinica
Abiomed, which is selling temporary heart assist machines and is working on what its CEO, Devid Lederman, calls the "last frontier in cardiac medicine" - the permanent, implantable, artificial heart - is clear about the significance of his company's final goal. Mr Lederman told the BancBoston Robertson Stephens conference earlier this month: "If you can replace the human heart, then a lot of other therapies will become superfluous."
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.